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A B S T R A C T
Orexinergic system is involved in reward processing and drug addiction. Objectives here, we investigated the
eﬀect of intra-hippocampal CA1 administration of orexin-1 receptor (OX1r) antagonist on the expression, and
extinction of morphine-induced place preference in rats. Conditioned place preference (CPP) was induced by
subcutaneous injection of morphine (5mg/kg) during a 3-day conditioning phase. Two experimental plots were
designed; SB334867 as a selective OX1r antagonist was dissolved in 12% DMSO, prepared in solutions with
diﬀerent concentrations (3, 30, and 300 nM), and microinjected into the CA1 and some neighboring regions
(0.5 μl/side), bilaterally. CPP score and locomotor activity were recorded during the CPP test. Results demon-
strated that intra-CA1 administration of the OX1r antagonist attenuates the expression of morphine-induced
CPP. Furthermore, higher concentrations of SB334867 facilitated the extinction period of morphine-induced CPP
and reduced its latency. Nevertheless, solely administration of DMSO did not have any inﬂuence on the CPP
scores and locomotion in both phases. Our ﬁndings suggest that OX1rs in the CA1 region of the hippocampus are
involved in the expression of morphine CPP. Moreover, blockade of OX1rs could facilitate extinction and may
extinguish the ability of drug-related cues. It seems that the antagonist might be considered as a propitious
therapeutic agent in suppressing drug-seeking behaviors.
1. Introduction
Repeated relapse is one challenge in the treatment of addiction. In
some addicts drug-craving is induced by drug-associated cues which
activate drug-associated memories after prolonged abstinence and then
lead to relapse. Conditioned place preference (CPP) paradigm is used
commonly for measuring of the rewarding properties of drugs in animal
through the Pavlovian conditioning [1,2]. Pharmacological studies
show that repeated drug administration produces drug reinforcement
and drug-induced place preference. Furthermore, CPP is also used to
study drug-related learning and memory and thus is suitable for
studying cue-induced responses [3]. Relapse has been modeled in an-
imal studies via measures of reinstated drug-seeking in animals ex-
tinguished from the drug. Sun et al. found that entrances to drug-paired
compartments, increased time-dependently in the rats. In the morphine
group, compared with the saline-paired compartments, rats entered
more frequently to the morphine-paired compartments in the CPP tests,
suggesting that rats had a more preference to the morphine- and saline-
associated environments [3]. Extinction related to a progressive de-
crease in the preference for the environment associated with the drug
when the substance is not present [4,5]. Reinstatement is widely ac-
cepted as a relevant model to study the mechanisms involved in drug-
craving and relapse is responding induced by a priming injection of
drugs [6,7] and more recently place-conditioning paradigm used for
observing a drug-induced reinstatement behavior [8–11]
The two major clinical concerns in the treatment of addiction are
the length of extinction period and reinstatement to drug [12]. It seems
the manipulation of the memories associated with any particular drug
could be an eﬀective method to remove these memories, and therefore
preventing relapse.
The hippocampus plays an important role in learning and memory
[13–15]. Previous studies have suggested that some of the cognitive
deﬁcits observed in opiate abusers may be related to altered hippo-
campal function [16]. Several lines of evidence demonstrating the in-
volvement of the hippocampus in CPP induced by drugs of abuse; it has
been shown that this region is involved in CPP task as a reward-related
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learning paradigm [17–19]. Dorsal hippocampus, especially the CA1
region, is a major neural substrate mediating the linkage between
contextual cues and the rewarding eﬀects of morphine [20]. The CA1
has a great output connections with the prefrontal cortex, bed nucleus
of the stria terminalis, the amygdale, ventral tegmental area (VTA),
nucleus accumbens (NAc) [21–23], and the amygdala has extensive
reciprocal connections with the ventral hippocampus [24]; all of these
structures have been applied in stress-related behaviors, such as drug-
seeking behavior in the reinstatement model of relapse [25].
Orexin-A and orexin-B (also called hypocretin-1 and hypocretin-2),
two key neuropeptides, are exclusively produced in a few number of
neurons in the perifornical area and posterior and lateral hypothalamus
(LH) [26,27]. The orexin system has a crucial role in regulation of the
motivated behaviors and brain reward [28,29].
Harris et al. showed that the induction of morphine- and cocaine-
CPP has a strong correlation with activation of lateral hypothalamic
orexin [30,31]. This study also reported that systemic administration of
the orexin-1 receptor (OX1r) antagonist, SB334867 blocks the re-
instatement of extinguished CPP behaviors. Subsequent studies showed
that systemic SB334867 blocks the expression of CPP for amphetamine
[32]. So, orexinergic neurons are involved in reward processing and
drug abuse [33]. Moorman et al. observed the strong activation of or-
exin neurons during context-induced reinstatement [34]. Also orexin
signaling via OX1r is critical for cue-induced reinstatement of ex-
tinguished cocaine-seeking in the self-administration paradigm [35].
The two bases of addiction are reward processing and drug abuse. It has
been hypothesized that conditioning mechanisms have major roles in
addiction. To be more speciﬁc, the association between the rewarding
properties of drug abuse and the drug context can contribute to future
use and therefore, it facilitates the transition from initial drug use into
drug dependency. Orexinergic neurons are activated by cues associated
with rewards such as drugs [30]; orexin neurons heavily innervate
structures that drive behaviors motivated by drug rewards. Moreover,
orexin receptors are expressed at high levels in the VTA and NAc
[36,37].
Morphological studies have shown that the hippocampal CA1 region
receives orexinergic innervation originating from the hypothalamus.
Positive OX1r are detected in the CA1 region. Orexin-A produces ex-
citatory eﬀects on hippocampal neurons via OX1rs in this region [38]. A
type of information is processed in the long-term memory which aﬀects
hippocampal-dependent learning, and it is regulated by the hippo-
campus-VTA dopaminergic loop [39], and orexinergic system can ac-
tivate mesolimbic dopamine neurons, especially those located in the
VTA [37,40]. Based on the importance of the CA1 region in mediating
reward processing and drug abuse, and also the existence of orexin
receptors in this area, the present experiments tried to determine the
eﬀects of infusions of SB334867 as a selective OX1r antagonist in the
dorsal hippocampus on expression and extinction of morphine-induced
conditioned place preference in the rats.
2. Materials and methods
2.1. Animals
In this study, seventy-eight adult male albino Wistar rats (Pasteur
Institute, Iran) weighing 220–280 g were used in this study. The ani-
mals were randomly kept in groups of three with free access to chow
and tap water. The vivarium was maintained at 12:12 h light/dark cycle
and controlled temperature (23 ± 1 °c). All experiments were con-
ducted according to the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health Publication No. 80-23, revised
1996) and were approved by the Research and Ethics Committee of
Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Additionally, all eﬀorts were made to minimize animal suﬀering and to
reduce the number of animals used to obtain reliable results.
2.2. Drugs
In this study, the used drugs were: Morphine sulfate (TEMAD, Iran),
SB334867, as an OX1r antagonist, (Tocris Bioscience, UK) which were
dissolved in sterile saline (0.9%) and 12% dimethyl sulfoxide (DMSO;
Sigma-Aldrich, Germany), respectively. Bilateral intra-CA1 microinfu-
sions of 0.5 μl of SB334867, DMSO 12%, were performed over 60 s
using a 1-μl Hamilton syringe connected to a stainless steel 30-gauge
needle as an 8-mm microinjector (1mm longer than the guide cannula)
which was attached to a piece of polyethylene tubing.
2.3. Cannulation methods
For stereotaxic implantation of cannulae, the rats were deeply an-
esthetized with intraperitoneal injection of a mixture of Ketamine and
Xylazine (100 and 10mg/kg, respectively) and placed in a stereotaxic
apparatus (Stoelting, USA). An incision was made along the midline,
the scalp was retracted, and the area surrounding bregma was cleaned
and dried. Stainless steel guide cannulae were unilaterally implanted
into 1mm above the CA1 according to the atlas of the rat brain [41].
Stereotaxic coordinates for the CA1 were AP=3.5 ± 0.15mm caudal
to bregma, Lat= 2.2 ± 0.7mm lateral to midline, DV=2.7mm ven-
tral from the skull surface (cannula 23-gauge, 9mm). The guide can-
nulae were secured in their places using two stainless steel screws an-
chored to the skull and dental acrylic cement. After the cement was
completely dried and hardened, cannula to prevent occlusion. After
5–7 days of recovery, animals were used for the experiments. Anato-
mical control injections groups, however, received the maximal dose of
drug (SB334867) alone into various neighboring regions of the CA1.
2.4. Conditioned place preference apparatus and paradigm
The CPP test, a behavioral task often used to measure reinforcing
properties of drugs, has been used to measure memory or learning of
simple stimulus-reward associations [2]. In order to evaluate these
features, a three-compartment CPP apparatus was used (Fig. 1). The
Fig. 1. Schematic three-chamber apparatus used in
the conditioned place preference paradigm.
S. Farahimanesh et al. Peptides 101 (2018) 25–31
26
apparatus was made of Plexiglas and divided into two equalsized and
cue-diﬀerent (distinguishable characteristics) compartments
(30× 30×40 cm) which were connected to each other via a start box
(30× 15×40 cm) as the third (null) compartment. The two main
compartments had a diﬀerence in their wall strips orientation (vertical
vs. horizontal) and for making the tactile diﬀerence between them, the
smooth and net panels were used for their ﬂoors. A guillotine door was
used to separate the two main compartments from the start box (Fig. 1).
The whole experimental process was performed under controlled light
conditions and in the silent room for avoiding any annoying sound. This
CPP procedure consists of a 5-day schedule with three distinct phases.
2.4.1. Pre-conditioning phase
During this phase (day1), each animal was placed in the start box
with the guillotine door removed and rats were allowed to move freely
in all compartments for a10-min period. Time spent in each compart-
ment was monitored and recorded using a 3CCD camera (Panasonic
Inc., Japan). In the experimental setup used in the present study, the
animals did not show any preference for either of the compartments
during the pre-conditioning phase. No injection was given on the pre-
conditioning day (pre-test day).
2.4.2. Conditioning phase
On the ﬁrst day of the conditioning phase (also known as the ac-
quisition phase, days 2–4), all groups received their allocated treatment
(Morphine 5mg/kg s.c., and intra- CA1 administration of drug/vehicle)
and were randomly conﬁned to the drug-paired compartment for
30min by closing the removable door of the apparatus. Six hours later,
all groups received saline subcutaneously without any intra-hippo-
campal treatment. Then, rats were placed in the non drug-paired
(saline-paired) compartment and their movements were recorded for
30min. On the second day, this process continued with the change in
the time of receiving the drugs. In other words, animals received sub-
cutaneous saline in the morning and their proper treatment in the
afternoon (6 h later). It was done to prevent any time-dependency on
drug administration. The third day of conditioning was performed the
same as the ﬁrst day.
2.4.3. Post-conditioning phase
On the ﬁfth day (expression phase), the animals were tested for the
CPP (under morphine-free condition) after receiving the allocated
treatment. Rats were placed in the box and tested for CPP with free
access to all compartments. The time spent in each compartment during
the 10-min period was recorded by a video tracking system for auto-
mation of behavioral experiments (Noldus Information Technology, the
Netherlands), 3CCD camera (Panasonic Inc., Japan), and analyzed
using the Ethovision software (Version 7). Diﬀerence(s) of the time
spent in the morphine and saline paired compartments were considered
as conditioning score (CPP score). No injection was given on the test
day. Total distance traveled (locomotor activity) by each animal was
also recorded in control and experimental groups.
2.4.4. Extinction latency
After conditioning and following the initial CPP test, rats underwent
the 20-min test session and the time spent in each compartment was
daily recorded by the Ethovision software, but no injections were per-
formed. This procedure was repeated for each animal in the control and
experimental groups and continued until the calculated CPP scores in
the extinction phase reach 50% decrease in CPP score in the test day
(post-conditioning day). The “extinction latency” for each animal was
represented by the number of days required to reach 50% decrease in
CPP score in the test day as a criterion.
2.5. Eﬀect of the treatments on locomotor activity
Any possible changes locomotor activity or any movement disorder
can aﬀect the CPP scores and procedure. Therefore, it is essential to
assure that locomotor activity of the animal (both ambulatory and
vertical movements) is normal. The total distance traveled (locomotor
activity) by each animal during a 10-min period was recorded by a
video tracking system and analyzed using the Ethovision software on
the test day (post-conditioning day).
2.6. Experimental design
2.6.1. Eﬀects of intra-CA1 injections of SB334867, as an OX1r antagonist,
on the expression of morphine-induced conditioned place preference
Animals were treated with morphine 5mg/kg (s.c.), once daily for 3
consecutive days. After conditioning days; Three SB-treated groups
(n= 21) were administered diﬀerent doses of SB334867 (3, 30 and
300 nM/0.5 μl DMSO) into the CA1 region, 5min prior to test in the
post-conditioning day. DMSO group (n=8) received 12% DMSO
(0.5 μl/rat) instead of SB334867 into the CA1 as a vehicle (morphine
control) group. An anatomical control injections group (n= 5) was
administered SB334867 as a 300 nM solution (the highest dose) into
various neighboring regions of the CA1. In all control and experimental
groups, CPP score and distance traveled were calculated during the10-
min period on the post-conditioning (test) day.
2.6.2. Eﬀects of intra-CA1 injections of SB334867, as an OX1r antagonist,
on the morphine extinction in conditioned place preference
In this set of experiments, we examined the eﬀect of intra-CA1 ad-
ministration of SB334867 (3, 30 and 300 nM/0.5 μl DMSO) on the
morphine maintenance. Three groups of animals (n= 20) received
diﬀerent doses of antagonists (3, 30 and 300 nM/0.5 μl DMSO) into the
CA1. In control groups, animals received 12% DMSO (n=5) as a ve-
hicle group, or the highest dose of SB334867 (n=6) as anatomical
control injections group during extinction days, 5 min before each test/
day. The naïve group was conditioned but did not receive any drug/
vehicle during extinction period. CPP scores and distance traveled were
calculated each day in extinction phase during the10-min period test.
2.7. Histological veriﬁcation
After completion of experimental sessions, animals were deeply
anesthetized with Ketamine and Xylazine. Then, they were transcar-
dially perfused with 0.9% saline and 10% formalin solution. The brains
were removed, blocked and cut coronally in 50-μm sections through the
cannula placements. Sections were examined to determine the location
of the cannulae (Fig. 2) aimed for the CA1 according to the rat brain
atlas [41]. Data from animals with injections sites located outside the
CA1 region were excluded from the main statistical analysis as mis-
placements. Additionally, another group of animals was used as ana-
tomical control injections in each set of experiment that received the
highest dose of SB334867 into the neighboring regions of the dorsal
hippocampus (Fig. 2).
2.8. Statistics
Conditioning scores were expressed as a mean ± standard error of
the mean (SEM). Also, locomotor activity was expressed as the total
distance traveled that the rats passed through compartments. Results
were considered statistically signiﬁcant when P < 0.05, and data were
analyzed using commercially available software GraphPad Prism® 6.0.
In order to study the eﬀect of treatments on the CPP scores and distance
traveled obtained in all groups during the expression, and extinction of
morphine-induced CPP, the statistical analyses were performed using
unpaired student t-test or one-way ANOVA followed by post-hoc
Newman-Keuls multiple comparison tests.
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3. Results
3.1. Eﬀects of intra-CA1 injections of SB334867, as an OX1r antagonist,
on the expression of morphine-induced conditioned place preference
In this set of experiments, we examined the eﬀects of diﬀerent doses
of SB334867 as an OX1r antagonist microinjected into the CA1 on
seeking behaviors in CPP paradigm. As shown in Fig. 3A, there was a
signiﬁcant diﬀerence in CPP scores [t12= 7.342, P < 0.001; Fig. 3A]
between saline control group (animals that received saline during 3-day
conditioning phase) compared to morphine control (DMSO) animals
that received morphine (5mg/kg; s.c.) during 3-day conditioning
phase, and also intra-CA1 injection of 12% DMSO (0.5 μl/side) instead
of SB334867 in post-conditioning day, just before the CPP test. How-
ever, one-way ANOVA followed by Newman-Keuls multiple comparison
tests [F (5, 39)= 17.81; P < 0.0001; Fig. 3A] demonstrated signiﬁcant
Fig. 2. The schematic illustrations of coronal sections of the rat brain showing the approximate location of the microinjection sites [white circle=DMSO, black circle= treatment
(SB334867), black square= anatomical control injections and black triangle=misplacement]. All microinjections were performed bilaterally into the CA1 or some neighboring regions
(e.g., CA2, CA3, DG, or MoDG). The numbers indicate A-P coordinates relative to bregma. Cornu Ammonis areas: CA1, CA2, CA3; D3V, dorsal third ventricle; LV, lateral ventricle; cc,
corpus callosum; ec, external capsule; DG, dentate gyrus; MoDG, molecular dentate gyrus. Atlas plates were adapted from the rat brain atlas (Paxinos and Watson 2007). Scale bar is
1 mm.
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diﬀerences in CPP scores between vehicle- and morphine-treated
groups on the test day. The results showed that the intra-CA1 admin-
istration of diﬀerent doses of SB334867 (30 and 300 nM/0.5 μl DMSO)
decreased CPP scores in the post-test day in a dose-dependent manner
compared to DMSO-control group. Here also, the highest concentration
of SB334867 notably blocked OX1rs within the CA1 and attenuated the
expression of place preference (P < 0.001), unlike the neighboring
regions which received SB334867 at the same concentration (300 nM).
On the other hand, one-way ANOVA followed by Newman-Keuls
multiple comparison tests [F (5, 39)= 0.2365; P=0.9436; Fig. 3B]
indicated that intra-CA1 administration of SB334867 did not change
distance traveled during the 10-min test period (post-conditioning
phase) in comparison with that of the vehicle-control groups.
3.2. Eﬀects of intra-CA1 injections of SB334867as an OX1r antagonist
during the extinction phase, on the extinction latency of morphine-induced
conditioned place preference
Fig. 4 determines the role of intra-CA1 orexin-1 receptors in the
extinction latency of morphine-induced CPP, after post-conditioning
phase, during extinction phase in a series of experiments. The extinc-
tion latency was deﬁned as a 50% decrease in CPP scores compared to
those of the ﬁfth day (post-conditioning). One-way ANOVA followed by
Newman-Keuls multiple comparison tests [F (5, 37)= 14.4;
P < 0.0001; Fig. 4A] showed that extinction latencies change in
treatment groups compared to the naïve and/or DMSO group. Intra-
Fig. 3. The eﬀect of bilateral administration of SB334867 (0.5 μl of 3, 30 and 300 nM
solutions per side) into the CA1 on (A) conditioning score(s) and (B) locomotor activity
with or without morphine during the expression phase. Following the experimental
procedure of morphine place conditioning, animals received SB334867 on the ﬁfth day.
After subcutaneous injections of saline and morphine during 3 days of conditioning,
DMSO (vehicle) group just received DMSO 12% (0.5 μl per side) into the CA1. After
3 days of conditioning with morphine, anatomical control injections group received a
300 nM solution of OX1r antagonist into some neighboring sites of the CA1, on day 5.
Additionally, diﬀerent doses of the SB334867 did not change distance traveled during the
10-min test period compared to that of the saline-control group. Each bar is represented
by the mean ± SEM for 5–8 rats (eight rats in DMSO group).
*P < 0.05, *** P < 0.001 compared to saline-control group.
†† P < 0.01, †††P < 0.001 compared to DMSO group.
Fig. 4. The eﬀect of administration of diﬀerent doses of SB334867 (3, 30 and 300 nM) on
(A) extinction latency (day), compared to naïve and/or DMSO control group that animal
received DMSO during extinction period instead of SB334867. Extinction latencies in
anatomical control injections group and animals which had received 3 nM solutions of
SB334867, were not signiﬁcantly changed compared to either naïve or DMSO groups.
Animals which had received 300 nM solutions of SB334867 notably showed more than
60% reduction in conditioning scores of day 5 compared to DMSO group. Additionally,
diﬀerent doses of the SB334867 did not change distance traveled during extinction period
compared to that of the naïve and/or DMSO groups. Each bar is represented by the
mean ± SEM for 5–7 rats.
*P < 0.05, *** P < 0.001compared to naïve group
†† P < 0.01 compared to DMSO group
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CA1 administration of SB334867 (30 and 300 nM) signiﬁcantly dis-
played shorter extinction latencies in these SB-treated groups
(4.5 ± 0.3 and 2 ± 0.3 days) compared to both naïve and/or DMSO
groups (6.4 ± 0.5 and 6.2 ± 0.5 days), respectively. Furthermore, as
shown in Fig. 4A, the extinction latency in the anatomical control in-
jections group (6 ± 0.7 days) had no changes compare to both naïve
and/or DMSO groups. On the other hand, one-way ANOVA followed by
Newman-Keuls multiple comparison tests [F (5, 37)= 0.1684;
P=0.9724; Fig. 4B] indicated that diﬀerent doses of SB334867 did not
change distance traveled during the 10-min test period (during ex-
tinction phase) in comparison with both naïve and/or DMSO groups.
4. Discussion
In the present study, the role of OX1rs within the dorsal hippo-
campus (CA1 region) in the expression and extinction of morphine-in-
duced CPP was investigated. The main research highlights were (i) a
reduction in the expression (retrieval of contextual information) of
drug-seeking behaviors and (ii) shortening the extinction latency of
morphine rewarding properties during the CPP paradigm by intra-CA1
administration of the OX1r antagonist, SB334867. Orexin transmission
in the hippocampal CA1 area through recruitment of the OX1rs is an
important issue in the expression of morphine-induced CPP. In addi-
tion, these ﬁndings conﬁrm that hippocampus has a role in the ex-
tinction of the model of Pavlovian conditioning [42], and it is crucial in
the exhibition of morphine-seeking behavior during the extinction
period.
Morphine injection into the hippocampus causes CPP [43]; it is
conﬁrmed that reward-related learning is associated with the hippo-
campus, meaning that it is involved in the formation of a connection
between the drug and particular contextual cues [44]. The CA3 and
CA1 are most likely involved in the reward processing; CA1 might play
a particularly crucial role among hippocampal sub-regions in evalu-
ating experienced events as well as reward, and chosen value signals
were stronger in CA1 than CA3 [45]. In this study, we showed that
CA1’s OX1r has a crucial role in this process. The LH sends projections
to CA1 that have an essential role in contextual reward-related beha-
viors [46]. The previous study in our lab revealed that chemical sti-
mulation of the LH by crabachol induces CPP in the rats [47–49]. Or-
exin neurons in the lateral subdivision of LH preferentially encode
reward-motivated behaviors and collaborate in brain reward [31]. In
addition, in the previous study, we found that unilateral intra-CA1
administration of SB334867, an OX1r antagonist, or TCSOX229, an
OX2r antagonist, signiﬁcantly attenuates the development of place
preference induced by stimulation of the LH in a dose-dependent
manner. This research indicates that the source of hippocampal orexins
could be the projecting neurons from LH [18]. It appears that orex-
inergic receptors, located in the dorsal hippocampus, are necessary for
the development of LH stimulation induced CPP.
Previous studies have shown that systemic administration of OX1r
antagonist leads to the reduction of the acquisition and expression of
morphine place preference [50]. A genetic deletion of orexin lacked
conditioned place preference for morphine in mice [51]. Primary stu-
dies in our laboratory have shown that the rewarding eﬀect of mor-
phine was disrupted by intra-hippocampal administration of OX1r an-
tagonist during the conditioning phase [19]. These ﬁndings are
consistent with our results and conﬁrm the critical role of OX1 re-
ceptors in the CA1 on the expression of CPP and reward processing. On
the other hand, bilateral intra-CA1 microinjection of TCS OX2 29 (OX2r
antagonist) signiﬁcantly prevented both acquisition and expression of
morphine-induced CPP [52]. This data is parallel with our ﬁndings the
CA1 orexinergic system is crucial for expression of morphine-induced
CPP. Therefore, in the present study, the intra-CA1 injection of OX1r
antagonist possibly disrupts memory retrieval associated cues and
context of CPP; in turn, it inhibits the expression of morphine-induced
CPP. In conclusion, our data provide evidence that orexinergic system
and its connections with CA1 have an essential role in the expression of
CPP induced by morphine.
We also found that drug-induced CPP or salience of drug-paired
environmental cues in the absence of morphine was maintained up to
8 days. Another ﬁnding from this research was that the intra-CA1 ad-
ministration of SB334867 after the test day (post-conditioning day)
could facilitate the extinction of morphine-induced CPP. This means
that the blockade of OX1rs and repeated exposure to the previously
drug-paired environment in the absence of the drug led to a reduction
in maintenance of morphine-induced CPP. Previous studies have shown
the interaction between the dorsal hippocampus and the basolateral
amygdale is necessary for the extinction of conditioned place aversion
(CPA) behavior [53]. Hippocampal OX1rs (particularly in the CA1) play
an essential role in other associative learning and memory processing
tasks such as CPA, fear conditioning, passive avoidance learning, and
Morris water maze task [54–56]. Orexin function during learning could
reﬂect its suggested role in mediating motivation and attention towards
biologically relevant events [57–59]. The reduction in the expression
(retrieval of contextual information) of drug-seeking behaviors and also
a facilitation in the extinction of morphine by intra-CA1 administration
of the OX1r antagonist, SB334867, in the current study could also re-
ﬂect a decrease in motivation and attention, or both of them. Indeed,
orexin signaling is necessary for the motivation to initially seek drugs
for reviews, see [31], and the motivation to seek reward during ex-
tinction [60,61]. Our ﬁndings are in agreement with previous reports.
Moreover, Flores et al. revealed that blockade OX1rs facilitated fear
extinction, whereas orexin-A administration impaired this extinction of
aversive memories [56]. Acute administration of SB334867 did not
aﬀect cocaine seeking or intake during the maintenance of self-ad-
ministration, but reduced cocaine seeking during extinction [62]. Our
data also showed that dorsal hippocampal OX1r antagonism facilitates
the extinction of reward memories; these ﬁndings are strictly in line
with a prominent role of hippocampal OX1rs in the associative learning
and memory processing.
In conclusion, the orexinergic system was evaluated in the expres-
sion phase of morphine reward and also during the extinction period of
the CPP paradigm. Our ﬁndings suggest that orexinergic signaling
through recruitment of OX1rs in the hippocampus has a crucial role in
the exhibition of reward-related behaviors during the expression and
extinction of morphine-induced CPP in the rats.
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